Which Healthcare ETF Is the Better Buy: Vanguard's VHT or Fidelity's FHLC?

Vanguard Health Care ETF (VHT) and Fidelity MSCI Health Care Index ETF (FHLC) offer nearly identical large-cap U.S. healthcare exposure (virtually the same top holdings and ~25% 1-year total returns: 25.20% vs 25.40%). The main differences are fund structure—FHLC is marginally cheaper (0.08% vs 0.09% expense ratio), while VHT pays a higher trailing dividend yield (1.60% vs 1.30%, a +0.30pp lead). VHT is also much larger ($20.4B AUM vs $3.2B) with similar risk outcomes (5-year max drawdown ~-17.7% for both).

Analysis

This is not a genuine relative-value setup between VHT and FHLC; it is a wrapper decision around the same underlying factor exposure. Because both are market-cap weighted and top-heavy in the same mega-cap names, any marginal inflow will mostly reinforce existing leadership rather than diversify it, which makes the real winners the index heavyweights with the largest free-float liquidity and balance-sheet durability. The fee edge is too small to matter unless an allocator is making repeated, very large, low-turnover purchases.

The second-order effect is flow concentration: if healthcare stays in favor as a defensive growth bucket, the passive bid will keep compressing valuation dispersion inside the sector and can leave smaller biotech/device names under-owned even if fundamentals improve. That makes stock-picking more valuable than ETF selection; the ETFs are effectively a high-conviction basket of a few large pharmas, so the alpha comes from deciding whether the sector leadership is durable, not from choosing the cheaper wrapper. For institutions, VHT’s larger asset base matters more for execution than for performance.

The main risk is that consensus is treating healthcare as a stable beta sleeve when it is actually a crowded consensus on a small set of winners. If GLP-1 enthusiasm or pharma M&A momentum stalls, both funds should de-rate in lockstep and there is little protection from choosing one over the other. The contrarian read is that the higher distribution yield is not a signal of superior economics; it is mostly a cash-flow presentation issue, so investors may be overpaying attention to the wrong variable.

Key Decisions for Investors

• No relative-value trade between VHT and FHLC; the spread is too small to justify active risk. If you need healthcare beta, choose VHT for institutional liquidity on larger tickets or FHLC for minimal fee drag on small recurring allocations; reassess only if one fund starts materially outperforming on tracking/flow over 3-6 months.
• Use any healthcare sector dip over the next 1-4 weeks to add LLY on pullbacks rather than buying the ETF basket; passive flows into VHT/FHLC mechanically favor the same top names, so stock ownership captures the flow concentration directly. Thesis fails if LLY guidance/margin commentary shows GLP-1 deceleration.
• For defensive income exposure, prefer ABBV or JNJ over trying to source alpha from the ETF choice; they are the main beneficiaries if allocator demand rotates toward healthcare for ballast. Watch 1-3 month sector flows: if healthcare AUM inflows do not accelerate, there is no reason to pay active attention to the ETF wrapper.
• Set an alert on sector leadership reversal: if healthcare underperforms the S&P 500 for 4-6 weeks while rates stabilize, exit any planned healthcare overweight; the current setup depends on persistent defensive demand, not a fresh fundamental catalyst.